Clareo Health | A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²)
Have either
* no T2D with an HbA1c \< 6.5% or
* have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.
Have been diagnosed with chronic kidney disease (CKD).
You may not be if
Have a self-reported change in body weight \>5 kilogram (kg) (11 pounds) within 90 days before screening.
Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin
Have a prior or planned surgical treatment for obesity
Have Type 1 Diabetes (T1D)
Have acute or chronic hepatitis
Have a history of malignant disease within 5 years before screening.
